At what pace is the cd20 antibody market growing, and what is its estimated value?
The CD20 antibody market size has grown rapidly in recent years. It will grow from $9.94 billion in 2024 to $10.99 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing prevalence of b-cell malignancies, rising incidence of autoimmune diseases, growing demand for targeted therapies, increasing approvals of biosimilars, rising healthcare expenditure, improving healthcare infrastructure and increasing awareness of immunotherapy benefits.
The CD20 antibody market size is expected to see rapid growth in the next few years. It will grow to $16.24 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to rising demand for advanced cancer immunotherapies, increasing prevalence of autoimmune disorders, growing adoption of biosimilar CD20 antibodies, expanding applications in combination therapies, increasing investment in biopharmaceutical research, growing awareness of personalized medicine. Major trends in the forecast period include development of next-generation CD20 antibodies, advancements in antibody-drug conjugates, integration of artificial intelligence in antibody design, improvements in bispecific antibody technology, rise of CAR-T cell therapies targeting CD20, adoption of nanotechnology for enhanced delivery, advancements in high-throughput screening methods.
Get Your Free Sample of The Global CD20 Antibody Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21131&type=smp
What are the top drivers to the rising demand in the cd20 antibody market?
The increasing incidences of B-cell malignancies are expected to propel the growth of the CD20 antibody market going forward. B-cell malignancies refers to the increasing number of cases of cancers that affect B cells, a type of white blood cell involved in the immune response. This can be attributed to several factors such as the aging population, genetic factors, environmental exposures, lifestyle, improved detection, and immune system changes. CD20 antibodies, such as rituximab, are used to target and deplete malignant B-cells in B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, enhancing treatment outcomes. For instance, in 2024, according to the report published by the American College of Cardiology, an US-based nonprofit medical association estimates that in 2025, approximately 80,350 people (45,140 males and 35,210 females), including both adults and children, will be diagnosed with non-Hodgkin lymphoma (NHL). Additionally, around 19,390 individuals (11,060 males and 8,330 females) are expected to die from this cancer. Therefore, the rising prevalence of B-cell malignancies is driving the growth of the CD-19 antibody market.
How is the cd20 antibody market segmented?
The CD20 antibody market covered in this report is segmented –
1) By Type: Monoclonal Antibody, Polyclonal Antibody
2) By Application: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Western Blot, Immunoprecipitation, Immunofluorescence
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Monoclonal Antibody: Rituximab, Obinutuzumab, Ofatumumab
2) By Polyclonal Antibody: Conventional Polyclonal Antibodies, Human Polyclonal Antibodies, Recombinant Polyclonal Antibodies
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/cd20-antibody-global-market-report
Who are the top competitors in the cd20 antibody market?
Major companies operating in the CD20 antibody market are F Hoffmann-La Roche AG, Merck & Co Inc, Thermo Fisher Scientific Inc, Novartis AG, GlaxoSmithKline plc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Biogen Inc, Genentech Inc, Bio-Rad Laboratories Inc, Genmab A/S, Bio-Techne, LFB Biotechnologies SA, Abcam Limited, Sino Biological Inc, Mylan NV, Immunomedics Inc, Spectrum Pharmaceuticals Inc, MyBiosource Inc, IGM Biosciences Inc, TG Therapeutics Inc
What significant trends should we anticipate in the cd20 antibody market over the forecast period?
Major companies operating in the CD20 antibody market are focusing on developing technological innovations such as biosimilars to enhance treatment accessibility, reduce healthcare costs, and address the growing demand for affordable and effective therapies for B-cell malignancies and autoimmune diseases. Biosimilars are biological medical products highly similar to an already approved reference product with no clinically meaningful differences in safety, purity, or efficacy. For instance, in July 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, announced that it had received a complete response letter (CRL) from the US Food and Drug Administration (USFDA) for its rituximab biosimilar candidate and would also work closely with the USFDA to address and resolve all concerns within the stipulated timelines aiming to make the biosimilar rituximab available to patients in the United States. Rituximab biosimilar works by targeting the CD20 protein on the surface of B-cells initiating a response that leads to the destruction of these abnormal or overactive B-cells.
Which regional trends are influencing the cd20 antibody market, and which area dominates the industry?
North America was the largest region in the CD20 antibody market in 2024. The regions covered in the CD20 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The CD20 Antibody Market Report 2025 Offer?
The cd20 antibody market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
CD20 antibodies are monoclonal antibodies that specifically target CD20, a protein found on the surface of B cells (a type of white blood cell involved in the immune response). These antibodies are used primarily to treat diseases related to abnormal B-cell function, such as cancers and autoimmune disorders. The main function of CD20 antibodies is to bind to the CD20 protein on B cells and trigger their destruction.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21131
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
